Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
公司代码XCUR
公司名称Exicure Inc
上市日期May 09, 2018
CEOYoo (Andy)
员工数量7
证券类型Ordinary Share
年结日May 09
公司地址2430 N. Halsted St.
城市CHICAGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编60614
电话18476731707
网址https://www.exicuretx.com/
公司代码XCUR
上市日期May 09, 2018
CEOYoo (Andy)